ArticleInternational journal of clinical and experimental medicine2015
Aqueous extract of Caesalpinia sappan decelerates allograft rejection by inducing imbalance between CD4(+) CD25(+) T cells and Th17 cells.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Immune response enhancement by dietary supplementation with Caesalpinia sappan extract in weaned pigs challenged with porcine reproductive and respiratory syndrome virus.BMC veterinary research · 2024Article
- Protective Effects ofFrontiers in pharmacology · 2021Review
- Brazilin Ameliorates Diabetic Nephropathy and Inflammation in db/db Mice.Inflammation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAqueous extract of Caesalpinia sappan (CSE) has immunosuppressive activities, but the mechanism remains unknown. This study was to investigate the effect of CSE on the balance between CD4(+) CD25(+) T cells and Th17 cells.
methodsAllografted Balb/c recipients were intraperitoneally treated with CSE for 14 continuous days, and the graft survival was observed. The spleen cells and peripheral blood of the recipient mice were harvested for phenotyping by flow cytometry, detection of gene expression by real-time PCR and cytokine detection by ELISA.
resultsCSE prolonged skin allograft survival, increased the percentage and number of CD4(+) CD25(+) T cells, the expression of Foxp3 and STAT5 in spleen cells, the serum levels of IL-10 and TGF-β1, whereas reduced the percentage and number of Th17 cells and serum IL-17 level in Balb/c recipients.
conclusionCSE expanded CD4(+) CD25(+) T cells and decreased Th17 cells in vivo thereby improving skin allograft survival in mice, indicating that CSE affects the balance between CD4(+) CD25(+) T cells and Th17 cells in the graft to induce rejection.
Indexed as
Identifiers
26221248PMC4509193W2427632274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.